Risk of drug-induced cardiac arrhythmia during COVID-19 therapeutic treatment

Abstract Therapeutic treatment of severe COVID-19 infection involves the administration of multiple pharmacologic agents to reduce the risk of serious complications; this may result in drug interactions and possible adverse reactions and induced cardiotoxicity. The risk–benefit ratio associated with...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Antonio Vitiello, Francesco Ferrara
Formato:	article
Lenguaje:	EN
Publicado:	SpringerOpen 2021
Materias:	Arrhytmia Cardiovascular Cardiac risk Pandemia Virology Diseases of the circulatory (Cardiovascular) system RC666-701
Acceso en línea:	https://doaj.org/article/40a3ae9a21a0429ea800947f1e0a5a57
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:40a3ae9a21a0429ea800947f1e0a5a57
record_format	dspace
spelling	oai:doaj.org-article:40a3ae9a21a0429ea800947f1e0a5a572021-11-21T12:27:00ZRisk of drug-induced cardiac arrhythmia during COVID-19 therapeutic treatment10.1186/s43044-021-00228-82090-911Xhttps://doaj.org/article/40a3ae9a21a0429ea800947f1e0a5a572021-11-01T00:00:00Zhttps://doi.org/10.1186/s43044-021-00228-8https://doaj.org/toc/2090-911XAbstract Therapeutic treatment of severe COVID-19 infection involves the administration of multiple pharmacologic agents to reduce the risk of serious complications; this may result in drug interactions and possible adverse reactions and induced cardiotoxicity. The risk–benefit ratio associated with the use of medications to treat COVID-19 should be carefully monitored. In addition, the severe COVID-19 patient may experience cardiac damage, and alteration of normal cardiac electrophysiology function. Severe COVID-19 with cardiac involvement and the risk of drug-induced adverse reactions may cause cardiac arrhythmias, including long qt syndrome, which in some cases may lead to sudden death. In this short review we briefly review the pharmacological agents used to treat severe COVID-19 with increased risk of causing long qt forms.Antonio VitielloFrancesco FerraraSpringerOpenarticleArrhytmiaCardiovascularCardiac riskPandemiaVirologyDiseases of the circulatory (Cardiovascular) systemRC666-701ENThe Egyptian Heart Journal, Vol 73, Iss 1, Pp 1-5 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	Arrhytmia Cardiovascular Cardiac risk Pandemia Virology Diseases of the circulatory (Cardiovascular) system RC666-701
spellingShingle	Arrhytmia Cardiovascular Cardiac risk Pandemia Virology Diseases of the circulatory (Cardiovascular) system RC666-701 Antonio Vitiello Francesco Ferrara Risk of drug-induced cardiac arrhythmia during COVID-19 therapeutic treatment
description	Abstract Therapeutic treatment of severe COVID-19 infection involves the administration of multiple pharmacologic agents to reduce the risk of serious complications; this may result in drug interactions and possible adverse reactions and induced cardiotoxicity. The risk–benefit ratio associated with the use of medications to treat COVID-19 should be carefully monitored. In addition, the severe COVID-19 patient may experience cardiac damage, and alteration of normal cardiac electrophysiology function. Severe COVID-19 with cardiac involvement and the risk of drug-induced adverse reactions may cause cardiac arrhythmias, including long qt syndrome, which in some cases may lead to sudden death. In this short review we briefly review the pharmacological agents used to treat severe COVID-19 with increased risk of causing long qt forms.
format	article
author	Antonio Vitiello Francesco Ferrara
author_facet	Antonio Vitiello Francesco Ferrara
author_sort	Antonio Vitiello
title	Risk of drug-induced cardiac arrhythmia during COVID-19 therapeutic treatment
title_short	Risk of drug-induced cardiac arrhythmia during COVID-19 therapeutic treatment
title_full	Risk of drug-induced cardiac arrhythmia during COVID-19 therapeutic treatment
title_fullStr	Risk of drug-induced cardiac arrhythmia during COVID-19 therapeutic treatment
title_full_unstemmed	Risk of drug-induced cardiac arrhythmia during COVID-19 therapeutic treatment
title_sort	risk of drug-induced cardiac arrhythmia during covid-19 therapeutic treatment
publisher	SpringerOpen
publishDate	2021
url	https://doaj.org/article/40a3ae9a21a0429ea800947f1e0a5a57
work_keys_str_mv	AT antoniovitiello riskofdruginducedcardiacarrhythmiaduringcovid19therapeutictreatment AT francescoferrara riskofdruginducedcardiacarrhythmiaduringcovid19therapeutictreatment
_version_	1718419001999097856

Risk of drug-induced cardiac arrhythmia during COVID-19 therapeutic treatment

Ejemplares similares